ENTRADA THERAPEUTICS, INC. Operating Expenses
ENTRADA THERAPEUTICS, INC. (TRDA) reported Operating Expenses of $45.86 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-05
- ENTRADA THERAPEUTICS, INC. operating expenses for the quarter ending 2026-06-30 was $45.86M, a 6.02% decline year-over-year.
- ENTRADA THERAPEUTICS, INC. operating expenses for the quarter ending 2026-03-31 was $43.18M, a 1.96% increase year-over-year.
- ENTRADA THERAPEUTICS, INC. operating expenses for the quarter ending 2025-12-31 was $43.51M, a 0.56% increase year-over-year.
- ENTRADA THERAPEUTICS, INC. operating expenses for the quarter ending 2025-09-30 was $48.66M, a 18.04% increase year-over-year.
- ENTRADA THERAPEUTICS, INC. operating expenses for fiscal 2025 was $183.32M, a 11.94% increase from fiscal 2024.
- ENTRADA THERAPEUTICS, INC. operating expenses for fiscal 2024 was $163.77M, a 23.90% increase from fiscal 2023.
- ENTRADA THERAPEUTICS, INC. operating expenses for fiscal 2023 was $132.18M, a 35.92% increase from fiscal 2022.
- ENTRADA THERAPEUTICS, INC. operating expenses for fiscal 2022 was $97.25M, a 90.21% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $45.86M 10-Q · filed 2026-08-05 | $89.04M 10-Q · filed 2026-08-05 | $132.55M derived: sum of 3 quarters · filed 2026-08-05 | $181.21M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $43.18M 10-Q · filed 2026-05-07 | $86.69M derived: sum of 2 quarters · filed 2026-05-07 | $135.35M derived: sum of 3 quarters · filed 2026-05-07 | $184.15M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $43.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $92.17M derived: sum of 2 quarters · filed 2026-02-26 | $140.97M derived: sum of 3 quarters · filed 2026-08-05 | $183.32M 10-K · filed 2026-02-26 |
| 2025-09-30 | $48.66M 10-Q · filed 2025-11-06 | $97.46M derived: sum of 2 quarters · filed 2026-08-05 | $139.81M 10-Q · filed 2025-11-06 | $183.08M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $48.80M 10-Q · filed 2026-08-05 | $91.15M 10-Q · filed 2026-08-05 | $134.41M derived: sum of 3 quarters · filed 2026-08-05 | $175.64M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $42.35M 10-Q · filed 2026-05-07 | $85.61M derived: sum of 2 quarters · filed 2026-05-07 | $126.84M derived: sum of 3 quarters · filed 2026-05-07 | $168.11M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $43.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $84.49M derived: sum of 2 quarters · filed 2026-02-26 | $125.76M derived: sum of 3 quarters · filed 2026-02-26 | $163.77M 10-K · filed 2026-02-26 |
| 2024-09-30 | $41.23M 10-Q · filed 2025-11-06 | $82.50M derived: sum of 2 quarters · filed 2025-11-06 | $120.51M 10-Q · filed 2025-11-06 | $157.45M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $41.27M 10-Q · filed 2025-08-06 | $79.28M 10-Q · filed 2025-08-06 | $116.22M derived: sum of 3 quarters · filed 2025-08-06 | $145.94M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $38.01M 10-Q · filed 2025-05-08 | $74.95M derived: sum of 2 quarters · filed 2025-05-08 | $104.67M derived: sum of 3 quarters · filed 2025-05-08 | $139.14M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $36.94M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $66.67M derived: sum of 2 quarters · filed 2025-02-27 | $101.14M derived: sum of 3 quarters · filed 2025-02-27 | $132.18M 10-K · filed 2025-02-27 |
| 2023-09-30 | $29.72M 10-Q · filed 2024-11-05 | $64.19M derived: sum of 2 quarters · filed 2024-11-05 | $95.23M 10-Q · filed 2024-11-05 | $120.81M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | $34.47M 10-Q · filed 2024-08-13 | $65.51M 10-Q · filed 2024-08-13 | $91.09M derived: sum of 3 quarters · filed 2024-08-13 | $117.02M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $31.04M 10-Q · filed 2024-05-07 | $56.62M derived: sum of 2 quarters · filed 2024-05-07 | $82.56M derived: sum of 3 quarters · filed 2024-05-07 | $106.14M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $25.58M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $51.52M derived: sum of 2 quarters · filed 2024-03-13 | $75.10M derived: sum of 3 quarters · filed 2024-03-13 | $97.25M 10-K · filed 2024-03-13 |
| 2022-09-30 | $25.94M 10-Q · filed 2023-11-07 | $49.52M derived: sum of 2 quarters · filed 2023-11-07 | $71.67M 10-Q · filed 2023-11-07 | $90.13M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $23.58M 10-Q · filed 2023-08-08 | $45.73M 10-Q · filed 2023-08-08 | $64.19M derived: sum of 3 quarters · filed 2023-08-08 | $78.56M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $22.15M 10-Q · filed 2023-05-10 | $40.61M derived: sum of 2 quarters · filed 2023-05-10 | $54.98M derived: sum of 3 quarters · filed 2023-05-10 | $64.89M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | $18.46M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | $32.82M derived: sum of 2 quarters · filed 2023-03-06 | $42.73M derived: sum of 3 quarters · filed 2023-03-06 | $51.13M 10-K · filed 2023-03-06 |
| 2021-09-30 | $14.36M 10-Q · filed 2022-11-07 | $24.27M derived: sum of 2 quarters · filed 2022-11-07 | $32.67M 10-Q · filed 2022-11-07 | $41.32M derived: sum of 4 quarters · filed 2022-11-07 |
| 2021-06-30 | $9.91M 10-Q · filed 2022-08-11 | $18.30M 10-Q · filed 2022-08-11 | $26.96M derived: sum of 3 quarters · filed 2022-08-11 | $33.93M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $8.39M 10-Q · filed 2022-05-12 | $17.05M derived: sum of 2 quarters · filed 2022-05-12 | $24.02M derived: sum of 3 quarters · filed 2022-05-12 | |
| 2020-12-31 | $8.65M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $15.63M derived: sum of 2 quarters · filed 2022-03-15 | $26.67M 10-K · filed 2022-03-15 | |
| 2020-09-30 | $6.97M 10-Q · filed 2021-12-09 | $18.01M 10-Q · filed 2021-12-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |